Healthcare
RenovoRx, Inc.(RNXT)
Live Price
Offline$0.8438
-2.45% today
1Y Change
-34.75%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $30.00M
- Revenue Growth
- +2511.6%
- EPS Growth
- +13.5%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RenovoRx, Inc. (RNXT) is a Healthcare stock with a market cap of $30.00M and listed on NASDAQ. The stock last traded around $0.84 and down 34.8% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +2511.6%, EPS growth of +13.5%, a dividend yield of 0.0%. What stands out right now is revenue +2511.6%, EPS +13.5%, free cash flow -20.1% with operating margin -1114.0% and ROIC -204.0%. Valuation already assumes a fairly strong business story at price/sales 27.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RNXT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+2511.6% vs +7.6% peer median
Operating Margin
Below sector median
-1114.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +2511.6% and EPS at +13.5%, with operating margin around -1114.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -11.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | +0.0% | +3.1% | โ |
2026 Mar 30, 2026 | +0.0% | -5.6% | -15.9% | -21.5% |
2025 Nov 13, 2025 | +0.0% | -23.0% | -20.1% | -1.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RNXT
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RNXT Max Drawdown
-48.38%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RNXT and SPY.
Company Overview
RenovoRx, Inc.
NASDAQ Capital Market
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
- Leadership
- Shaun R. Bagai
- IPO Date
- Aug 26, 2021
- Employees
- 10
- Street Address
- 4546 El Camino Real
- Mailing
- Mountain View, CA, 94022
- Region
- Mountain View, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 284 4433
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 27.6
- Price/Book
- 5.8
Growth
- Revenue
- +2511.6%
- EPS
- +13.5%
- Free Cash Flow
- -20.1%
Profitability
- Gross Margin
- 70.9%
- Operating Margin
- -1114.0%
- Net Margin
- -994.5%
- ROE
- -119.8%
- ROIC
- -204.0%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 4.02
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.